

Bora Pharmaceuticals Reports Consolidated Revenue of NT\$1.72 Billion in October

保瑞公告 10 月自結合併營收新台幣 17 億 2 仟萬元

Taipei, Taiwan, November 10, 2025 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) announced that its consolidated revenues for October 2025 reached NT\$1.72 billion, a decrease of 17.9% compared to same period last year of which 4-5% was attributable to foreign-exchange translation effects. The Company noted that the New Taiwan Dollar is expected to remain in the range of NTD 30–31 per USD. Year-to-date, the Company delivered a 6.6% growth over last year.

台北，台灣，2025 年 11 月 10 日 – 保瑞藥業（以下簡稱「保瑞」，股票代碼：6472）今日公告 10 月自結合併營收為新台幣 17 億 2 仟萬元，較去年同期衰退 17.9%，美元匯兌維持在 30-31 區間影響營收約新台幣 1 億元；累計營收較去年增長 6.6%。

The Company expects CDMO business to maintain its upward momentum during the quarter mostly contributed by the Maryland fill/finish facility. Amid the growing onshoring wave, the demand for US fill-finish production has become a clear wedge of differentiation and strategic focus. After a period of steady expansion, 2025 was another pivotal year for Bora’s growth and industry leadership. In July, the Company expanded its Canadian facility with the addition of advanced filling technology, increasing annual production capacity to more than 50 million units. Shortly after, Bora unveiled a multi-year development plan for its Maple Grove, Minnesota site, including the build-out of 100,000 square feet of new manufacturing and packaging space. These strategic investments further increase capacity while positioning Bora to meet rising demand across a growing range of drug programs.

保瑞預期馬里蘭州針劑廠在第四季將持續扮演增長領頭羊，在美國製造聲浪中，針劑充填的在地製造需求尤為明確，是保瑞提前布局差異化製造的里程碑，亦是第四季 CDMO 持續增長的動能。在經歷數年的穩健擴張後，2025 年對保瑞而言是成長性與深化產業領導地位的重要轉折點。今年 7 月，保瑞擴建其位於加拿大的廠區，新增先進皮膚科用藥充填技術，年產能提升至超過 5,000 萬劑。隨後，公司發布了美國明尼蘇達州 Maple Grove 廠的中期開發藍圖，充實 10 萬平方英尺的製造與包裝空間。這些策略性資本支出使得保瑞穩固其在全球製藥代工市場的關鍵地位。

Bora is honored to share that it was named this year’s winner of the Biotech Breakthrough Awards’ Overall Biotech Company of the Year award. The honor recognized Bora’s unique ability to provide the hands-on reliability of a dedicated partner with the infrastructure and scale of a global leader.

在製藥界盛事CPHI甫落幕之際，保瑞宣布榮獲 Biotech Breakthrough Awards 「年度最佳生技公司（Overall Biotech Company of the Year）」大獎。此項殊榮肯定了保瑞在全球生技產業中展現的獨特實力，在現下政經環境中發展出的兼具「專業夥伴穩定可靠的品質」與「國際領導者的規模與服務架構」，在持續成長與全球佈局之間展現卓越的平衡與執行力。

About Bora:

Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", 6472.TW) is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

<https://www.bora-corp.com>

<https://www.boracdm.com>

關於保瑞：

保瑞藥業股份有限公司（股票代碼：6472）成立於2007年，是一家領先的製藥服務公司，自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO（委託開發與製造服務）與藥物開發銷售的「雙引擎」商業模式，協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域，致力於透過拓展銷售通路實力提升患者的生活品質。

透過持續投資人才、生產與銷售及進入生物製劑業務領域，保瑞不斷推動業務升級與永續發展。我們以Making Success More Certain為使命，專注高品質、高效率與可靠性，在製藥及 CDMO 領域樹立新標杆。

請造訪：

企業網站 <https://www.bora-corp.com>

CDMO 網站 <https://www.boracdm.com>

Investor/Media enquiries 新聞聯繫人：

Nadiya Chen, Investor Relations 投資人關係 陳荻雅

+886 2 790-1555 Ext. 9108

Email : Nadiya.Chen@bora-corp.com